Skip to main content
. 2020 May 13;395(10239):1771–1778. doi: 10.1016/S0140-6736(20)31103-X

Table 2.

Comparison between patients with Kawasaki-like disease presenting before and after the SARS-CoV-2 epidemic

Group 1 Group 2 p value
Time of presentation Until February, 2020 March–April, 2020 NA
Number of patients 19 10 NA
Age at onset, years 3·0 (2·5) 7·5 (3·5) 0·00035
Incidence 0·3 per month 10 per month <0·00001
Sex NA NA 0·13
Female 12 3 NA
Male 7 7 NA
Incomplete Kawasaki disease 6/19 (31%) 5/10 (50%) 0·43
CRP, mg/dL 16·3 (8·0) 25 (15·3) 0·05
ESR, mm/h 82 (29) 72 (24) 0·38
White cell count, × 109 per L 19·4 (6·4) 10·8 (6·1) 0·0017
Neutrophils 71·9% (17·2) 84·5% (5·7) 0·034
Lymphocytes, × 109 per L 3·0 (1·8) 0·86 (0·4) 0·0012
Haemoglobin, g/dL 10·8 (2·0) 11 (1·2) 0·79
Platelets, × 109 per L 457 (96) 130 (32) <0·00001
Albumin, g/dLl 3·3 (0·5) 3·2 (0·3) 0·55
Sodium, mEq/L 134·7 (1·6) 130·8 (3·9) 0·0011
AST, U/L 120 (218) 87 (70) 0·64
ALT, U/L 92 (122) 119 (217) 0·67
Ferritin, ng/mL 187 (89) 1176 (1032) 0·011
Triglycerides, mg/dL .. 239 (108) ..
Fibrinogen, mg/dL 543 (300) 621 (182) 0·51
D-dimer, ng/mL 3244 (943) 3798 (1318) 0·52
CPK, IU/L 61 (28) 85 (64) 0·19
Troponin I, ng/L .. 1004 (1862) ..
proBNP, ng/L .. 1255 (929) ..
Kobayashi score ≥5 2/19 (10%) 7/10 (70%) 0·0021
MAS18 0/10 (0%) 5/10 (50%) 0·021
KDSS14 0/10 (0%) 5/10 (50%) 0·021
Abnormal echocardiography 2/19 (10%) 6/10 (60%) 0·0089
Adjunctive steroid treatment 4/19 (16%) 8/10 (80%) 0·0045
Inotropes treatment 0/19 (0%) 2/10 (20%) 0·11
Response to treatment 19/19 (100%) 10/10 (100%) 1

Data are mean (SD) or n/N (%), unless otherwise stated. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. NA=not applicable. CRP=C-reactive protein. ESR=erythrocyte sedimentation rate. AST=aspartate aminotransferase. ALT=alanine aminotransferase. CPK=creatine phosphokinase. BNP=B-type natriuretic peptide. MAS=Macrophage Activation Syndrome. KDSS=Kawasaki disease shock syndrome.